Why the study?
A third of acute coronary events in Australia occur in patients with established coronary heart disease, prompting evaluation of the prognostic value of combined BNP measurement and quantitative MPS data for cardiac events.
Does combined B-type natriuretic peptides (BNP) measurement and quantitative myocardial perfusion scan (MPS) improve prediction of cardiac events in patients who have previously undergone percutaneous coronary intervention (PCI)?
Does combined B-type natriuretic peptides (BNP) measurement and quantitative myocardial perfusion scan (MPS) improve prediction of cardiac events in patients who have previously undergone percutaneous coronary intervention (PCI)?
Answers are grounded in this paper and cite their sources.
Combined BNP measurement and myocardial perfusion scanning offers high sensitivity and specificity for predicting cardiac events in patients post-PCI, suggesting utility for secondary prevention.
INTRODUCTION: A third of all acute coronary events that present in the Australian population occur in patients with established coronary heart disease. This study assessed the prognostic value of combined B-type natriuretic peptides (BNP) measurement and quantitative myocardial perfusion scan (MPS) data for cardiac events (CE). MATERIAL AND METHODS: This retrospective cohort study involved 133 patients from rural Western Australia. The cut-off for normality was 6.0 for qualitative summed difference scores (SDS) of MPS and 400 pg/mL for BNP. RESULTS: Patients with no CE had a mean SDS and BNP (1.52 with a 95% CI of 0.34 to 2.69), (175.9 with a 95% CI of 112.7-239.1) that was lower than patients with CE (6.54 with 95% CI 4.18-9.89) (P = 0.0003), (669.1 with 95% CI 543.9-794.3) (P < 0.0001). The sensitivity and specificity of combined testing for predicting CE respectively were 79.6% and 86.3% for SDS, 84.6% and 94.1% for BNP, and 100% and 92.7% for SDS and BNP combined. DISCUSSION AND CONCLUSION: Elevated BNP is marginally superior to MPS in predicting CEs in patients who have previously undergone percutaneous coronary intervention (PCI); however, MPS can identify the region of myocardium most at risk. Routine BNP monitoring in this subgroup may serve as secondary prevention by identifying subclinical disease.
No takes yet. Share an insight, caveat, or question.
Tually et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: